Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/nanoparticle-diagnostics.md — the filesystem corpus, unchanged. Not an edit.
12.9 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["nanomedicine"]categories: ["nanomedicine"]tags: ["nanomedicine", "diagnostics", "liquid biopsy", "cancer screening", "nanopore", "biomarkers"]tags: ["nanomedicine", "diagnostics", "liquid biopsy", "cancer screening", "nanopore", "biomarkers"]summary: "Detection methods that read single molecules or use nanoscale labels, including liquid biopsy, multi-cancer blood tests, and nanopore sensing, together with their overdiagnosis costs."summary: "Detection methods that read single molecules or use nanoscale labels, including liquid biopsy, multi-cancer blood tests, and nanopore sensing, together with their overdiagnosis costs."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Tumour genotyping from blood is routine care, and a randomized trial used circulating tumour DNA to guide chemotherapy in stage II colon cancer; no multi-cancer blood test has been shown to reduce mortality in people."humanEvidence: "Tumour genotyping from blood is routine care, and a randomized trial used circulating tumour DNA to guide chemotherapy in stage II colon cancer; no multi-cancer blood test has been shown to reduce mortality in people."access: "Lateral flow tests and tumour genotyping are routine clinical care; a cell-free DNA colorectal screen was approved in the United States in 2024, and multi-cancer tests are sold outside organised screening programmes rather than reimbursed by them."access: "Lateral flow tests and tumour genotyping are routine clinical care; a cell-free DNA colorectal screen was approved in the United States in 2024, and multi-cancer tests are sold outside organised screening programmes rather than reimbursed by them."reversibility: "reversible"reversibility: "reversible"lines 25–87 → 25–8710 unchanged lines not shown
{ "label": "Signal fraction in early disease", "value": "Often below 0.1%" }, { "label": "Signal fraction in early disease", "value": "Often below 0.1%" }, { "label": "cfDNA colorectal screen approved", "value": "United States, 2024" }, { "label": "cfDNA colorectal screen approved", "value": "United States, 2024" }, { "label": "Principal tradeoff", "value": "Overdiagnosis and false positives" }, { "label": "Principal tradeoff", "value": "Overdiagnosis and false positives" }, { "label": "Readiness", "value": "TRL 8–9 by format" } { "label": "Readiness", "value": "TRL 8-9 by format" } ] ]}}`````` **Nanoscale diagnostics** covers detection methods that operate on individual molecules or use nanoscale particles as labels and sensors. The category spans the mundane and the frontier: the coloured line on a home antigen test is a stripe of gold nanoparticles, while single-molecule sequencing through an engineered pore reads a DNA strand base by base. The clinically consequential branch as of 2026 is the blood test for fragments of tumour DNA, which is closer to changing cancer screening than any other technology in this wiki's nanomedicine section.**Nanoscale diagnostics** covers detection methods that operate on individual molecules or use nanoscale particles as labels and sensors. The category runs from the mundane to the frontier. The coloured line on a home antigen test is a stripe of gold nanoparticles, while single-molecule sequencing through an engineered pore reads a DNA strand base by base. As of 2026 the branch with the most clinical consequence is the blood test for fragments of tumour DNA, which is closer to changing cancer screening than any other technology in this wiki's nanomedicine section. ## Nanoparticle labels## Nanoparticle labels The oldest working application uses nanoparticles as visible or magnetic reporters. Colloidal gold conjugated to antibodies aggregates at a capture line on a nitrocellulose strip, producing the red band of a lateral flow test; the format is cheap, needs no instrument, and was manufactured in billions of units during the COVID-19 pandemic. Superparamagnetic iron oxide particles serve as magnetic resonance contrast agents and, in one cleared platform, as the readout for detecting bloodstream pathogens by their effect on water relaxation times, avoiding the delay of culture.The oldest working application uses nanoparticles as visible or magnetic reporters. Colloidal gold conjugated to antibodies aggregates at a capture line on a nitrocellulose strip and produces the red band of a lateral flow test. The format is cheap, needs no instrument, and was manufactured in billions of units during the COVID-19 pandemic. Superparamagnetic iron oxide particles are used as magnetic resonance contrast agents. In one cleared platform they are also the readout for detecting bloodstream pathogens by their effect on water relaxation times, which avoids the delay of culture. Quantum dots — semiconductor nanocrystals with narrow, size-tunable emission — became standard in research imaging and multiplexed assays but have made little clinical progress, partly because the brightest formulations contain cadmium.Quantum dots, semiconductor nanocrystals with narrow, size-tunable emission, became standard in research imaging and multiplexed assays but have made little clinical progress, partly because the brightest formulations contain cadmium. These are labels rather than sensors. The engineering that matters is surface chemistry: keeping particles from aggregating, attaching antibodies at the right density, and preventing non-specific binding. It is the same body of knowledge that governs [[targeted-drug-delivery]], applied to a much easier problem, because a particle in a test strip does not have to survive blood, evade phagocytes, or find an organ.These particles are labels rather than sensors, and the engineering that matters is surface chemistry: keeping particles from aggregating, attaching antibodies at the right density, and preventing non-specific binding. The same body of knowledge governs [[targeted-drug-delivery]]. A test strip is a much easier problem, because a particle in it does not have to survive blood, evade phagocytes, or find an organ. ## Liquid biopsy## Liquid biopsy Cell-free DNA circulates in plasma in everyone. Tumours shed their own, and that circulating tumour DNA carries the mutations, copy-number changes, and methylation patterns of the cancer that produced it. Sampling it means sampling a tumour without a needle, repeatedly, and capturing heterogeneity a single core biopsy would miss.Cell-free DNA circulates in plasma in everyone. Tumours shed their own, and that circulating tumour DNA carries the mutations, copy-number changes, and methylation patterns of the cancer that produced it. Sampling it means sampling a tumour without a needle, repeatedly, and capturing heterogeneity that a single core biopsy would miss. The technical difficulty is signal fraction. In advanced disease tumour DNA may be a few percent of the total; in early-stage disease it is often below one part in a thousand, so detection requires deep sequencing, molecular barcoding to distinguish real variants from sequencing errors, and statistical models that aggregate weak evidence across many sites. Methylation-based methods have proved more sensitive than mutation-based ones for early detection, because a tumour genome carries far more differentially methylated positions than driver mutations, and the pattern also indicates the tissue of origin. The same methylation arrays and sequencing panels underlie the [[epigenetic-clock]] literature, which reads the marks for a different purpose and faces a much weaker validation standard.The technical difficulty is signal fraction. In advanced disease tumour DNA may make up a few percent of the total; in early-stage disease it is often below one part in a thousand. Detection therefore requires deep sequencing, molecular barcoding to distinguish real variants from sequencing errors, and statistical models that aggregate weak evidence across many sites. Methylation-based methods have proved more sensitive than mutation-based ones for early detection, because a tumour genome carries far more differentially methylated positions than driver mutations, and the pattern also indicates the tissue of origin. The same methylation arrays and sequencing panels underlie the [[epigenetic-clock]] literature, which reads the marks for a different purpose and faces a much weaker validation standard. Three applications have separated out. Genotyping advanced cancers to select targeted therapy is routine practice. Minimal residual disease testing after surgery detects recurrence months before imaging and has been used in randomised trials to decide who needs adjuvant chemotherapy, in one colon cancer study reducing chemotherapy use without worsening recurrence-free survival.[^tie2022] Screening asymptomatic people is the most consequential and the least settled.Three applications have separated out. Genotyping advanced cancers to select targeted therapy is routine practice. Minimal residual disease testing after surgery detects recurrence months before imaging and has been used in randomised trials to decide who needs adjuvant chemotherapy; in one colon cancer study it reduced chemotherapy use without worsening recurrence-free survival.[^tie2022] Screening asymptomatic people is the most consequential application and the least settled. ## Multi-cancer early detection## Multi-cancer early detection Multi-cancer early detection tests look for a shared signal across dozens of cancer types in a single blood draw, most using methylation patterns. In a prospective study of several thousand adults, just over a third of positive signals corresponded to a confirmed cancer, with specificity above 99 percent.[^schrag2023] A specificity of 99 percent sounds excellent and is not, when the prevalence of undiagnosed cancer in a screened population is well under one percent: most positives in such a setting are false, and each one triggers imaging, biopsy, and months of uncertainty.Multi-cancer early detection tests look for a shared signal across dozens of cancer types in a single blood draw, most of them using methylation patterns. In a prospective study of several thousand adults, just over a third of positive signals corresponded to a confirmed cancer, with specificity above 99 percent.[^schrag2023] That specificity is less impressive than it sounds when the prevalence of undiagnosed cancer in a screened population is well under one percent. In such a setting most positives are false, and each one triggers imaging, biopsy, and months of uncertainty. A single-cancer version cleared the regulatory bar first. A blood test for colorectal cancer approved in the United States in 2024 detected about 83 percent of cancers at 90 percent specificity in a large screening cohort, but only about 13 percent of advanced precancerous lesions.[^chung2024] That asymmetry matters: colonoscopy prevents cancer by removing adenomas, whereas a blood test that misses nearly nine in ten of them mostly finds disease that has already arrived. Its plausible value is in reaching people who decline colonoscopy at all.A single-cancer version cleared the regulatory bar first. A blood test for colorectal cancer, approved in the United States in 2024, detected about 83 percent of cancers at 90 percent specificity in a large screening cohort, but only about 13 percent of advanced precancerous lesions.[^chung2024] The gap matters because colonoscopy prevents cancer by removing adenomas, whereas a blood test that misses nearly nine in ten of them mostly finds disease that has already arrived. Its plausible value lies in reaching people who decline colonoscopy altogether. The largest randomised trial of multi-cancer screening, enrolling roughly 140,000 people in England, was designed to measure whether the approach reduces late-stage diagnoses. As of 2026 no national screening programme has adopted a multi-cancer blood test.The largest randomised trial of multi-cancer screening, which enrolled roughly 140,000 people in England, was designed to measure whether the approach reduces late-stage diagnoses. As of 2026 no national screening programme has adopted a multi-cancer blood test. > [!caution] The screening trap> [!caution] The screening trap> Finding cancer earlier is not the same as helping patients. Lead-time bias makes survival from diagnosis look longer whenever diagnosis moves earlier, even if death occurs at the same moment. Length bias means screening preferentially catches slow-growing tumours, which are the ones least likely to kill. Only a reduction in mortality, measured against an unscreened control arm, distinguishes benefit from statistical artefact.> Finding cancer earlier does not by itself help patients. Lead-time bias makes survival from diagnosis look longer whenever diagnosis moves earlier, even if death occurs at the same moment. Length bias means screening preferentially catches slow-growing tumours, which are the ones least likely to kill. Only a reduction in mortality, measured against an unscreened control arm, distinguishes benefit from statistical artefact. ## Overdiagnosis## Overdiagnosis Overdiagnosis is the detection of disease that would never have caused symptoms. It is not a false positive: the cancer is really there under the microscope. It would simply never have progressed.Overdiagnosis is the detection of disease that would never have caused symptoms. It differs from a false positive: the cancer is really there under the microscope, but it would never have progressed. The clearest natural experiment came from South Korea, where widespread ultrasound screening of the thyroid increased diagnosed incidence many times over while mortality from thyroid cancer stayed flat — the signature of finding disease that did not need finding.[^ahn2014] Most of those patients had their thyroid removed and took hormone replacement for life.The clearest natural experiment came from South Korea. Widespread ultrasound screening of the thyroid there increased diagnosed incidence many times over while mortality from thyroid cancer stayed flat, the signature of finding disease that did not need finding.[^ahn2014] Most of those patients had their thyroid removed and took hormone replacement for life. Blood-based multi-cancer tests could reproduce this at scale, or could avoid it. The optimistic argument is that a tumour shedding enough DNA to be detected is metabolically active and therefore more likely to be consequential, which would make the modality biased toward aggressive disease rather than indolent disease. The argument is plausible and unproven; the evidence that would settle it is mortality data from randomised trials that are due to report over the coming years.Blood-based multi-cancer tests could reproduce this at scale, or could avoid it. The optimistic argument holds that a tumour shedding enough DNA to be detected is metabolically active and therefore more likely to be consequential, which would bias the modality toward aggressive rather than indolent disease. The argument is plausible and unproven. The evidence that would settle it is mortality data from randomised trials due to report over the coming years. ## Single-molecule sensing## Single-molecule sensing Nanopore sensing threads a molecule through a protein or solid-state pore a few nanometres wide and reads the resulting change in ionic current. The principle was demonstrated for polynucleotides in 1996 and became a commercial sequencing platform in the 2010s, giving very long reads from a device that fits in a hand and that has been used for genomic surveillance during outbreaks in field conditions.[^kasianowicz1996] Work on reading peptides and post-translational modifications by the same method has advanced considerably, and if it matures it would provide something proteomics currently lacks: single-molecule sequencing of proteins.Nanopore sensing threads a molecule through a protein or solid-state pore a few nanometres wide and reads the resulting change in ionic current. The principle was demonstrated for polynucleotides in 1996 and became a commercial sequencing platform in the 2010s. The platform gives very long reads from a device that fits in a hand, and it has been used for genomic surveillance during outbreaks in field conditions.[^kasianowicz1996] Work on reading peptides and post-translational modifications by the same method has advanced considerably. If it matures, it would provide something proteomics currently lacks: single-molecule sequencing of proteins. A different route uses [[crispr-cas9]] machinery as a detector. Collateral cleavage by certain Cas enzymes, triggered when a guide RNA finds its target, cuts a labelled reporter and produces a fluorescent or lateral-flow signal, allowing nucleic acid detection at low cost without thermal cycling.A different route uses [[crispr-cas9]] machinery as a detector. When a guide RNA finds its target, certain Cas enzymes begin collateral cleavage and cut a labelled reporter, producing a fluorescent or lateral-flow signal. The method detects nucleic acids at low cost without thermal cycling. Activity-based synthetic biomarkers invert the usual approach. Rather than looking for a molecule the body produces, they inject a nanoparticle carrying peptide substrates for disease-associated proteases; cleavage releases reporter fragments that concentrate in urine, amplifying a local enzymatic activity into an easily measured signal.[^kwong2013] The approach remains in early clinical development. It is the closest working thing to a diagnostic nanodevice: an injected particle that performs a computation of sorts in tissue and reports the answer, though without any of the autonomy the designs in [[medical-nanorobots]] assume. Structural containers built by [[dna-nanotechnology]] and the steerable devices of [[microrobots-in-medicine]] have both been proposed as sensing platforms, and neither has entered human testing.Activity-based synthetic biomarkers invert the usual approach. Rather than looking for a molecule the body produces, they inject a nanoparticle carrying peptide substrates for disease-associated proteases. Cleavage releases reporter fragments that concentrate in urine, amplifying a local enzymatic activity into an easily measured signal.[^kwong2013] The approach remains in early clinical development. It is the closest working thing to a diagnostic nanodevice, an injected particle that performs a computation of sorts in tissue and reports the answer, though it has none of the autonomy the designs in [[medical-nanorobots]] assume. Structural containers built by [[dna-nanotechnology]] and the steerable devices of [[microrobots-in-medicine]] have both been proposed as sensing platforms, and neither has entered human testing. ## Limitations and outlook## Limitations and outlook Analytical sensitivity has outrun clinical interpretation. Detecting a hundred tumour DNA molecules in a tube of blood is now tractable; knowing what to do about them frequently is not, and clonal haematopoiesis — mutated blood cell clones that accumulate with age and shed the same variants tumours do — is a persistent source of confusing signals that also connects these assays to the biology of [[stem-cell-exhaustion]] and, more broadly, to the somatic mutation entry in the [[hallmarks-of-aging]].Analytical sensitivity has outrun clinical interpretation. Detecting a hundred tumour DNA molecules in a tube of blood is now tractable; knowing what to do about them frequently is not. Clonal haematopoiesis, in which mutated blood cell clones accumulate with age and shed the same variants tumours do, is a persistent source of confusing signals. It also connects these assays to the biology of [[stem-cell-exhaustion]] and, more broadly, to the somatic mutation entry in the [[hallmarks-of-aging]]. Cost and access shape who benefits. A test priced for self-pay markets, delivered outside organised screening programmes and increasingly alongside the panels covered under [[consumer-blood-testing]], tends to reach people already well served by medicine, which is the pattern described in [[access-and-inequality]]. Insurance and employment consequences of a positive result raise the questions covered in [[genetic-discrimination]].Cost and access shape who benefits. A test priced for self-pay markets and delivered outside organised screening programmes, increasingly alongside the panels covered under [[consumer-blood-testing]], tends to reach people already well served by medicine, the pattern described in [[access-and-inequality]]. Insurance and employment consequences of a positive result raise the questions covered in [[genetic-discrimination]]. The most interesting unresolved application is not cancer at all. If the same sequencing and proteomic depth were applied longitudinally to healthy people, it might supply the surrogate endpoints that the field of [[aging-biomarkers]] has been unable to validate, put a measurement behind claims about [[biological-age]], and give trials in [[geroscience-hypothesis]] something to measure other than death. Whether a molecular signal read from plasma can track something as diffuse as biological ageing, rather than a discrete tumour, is a much harder question than early cancer detection, and no assay has yet answered it.One unresolved application lies outside cancer. If the same sequencing and proteomic depth were applied longitudinally to healthy people, it might supply the surrogate endpoints that the field of [[aging-biomarkers]] has been unable to validate, put a measurement behind claims about [[biological-age]], and give trials in [[geroscience-hypothesis]] something to measure other than death. Whether a molecular signal read from plasma can track something as diffuse as biological ageing, rather than a discrete tumour, is a much harder question than early cancer detection, and no assay has yet answered it. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
83 lines are the same in both revisions, and 35 of them are not shown. Neither revision here is necessarily the current article — read Nanoscale diagnostics for the text this wiki stands behind today.